Table 5.

Age and multivariable-adjusted risk of glioma in NHS, NHSII, and HPFS by type of statin use, using Cox proportional hazard modeling

	Women (n = 131)a			Men (n = 72)			Total (n = 203)b
	Cases	Hazard ratio	95% CI	Cases	Hazard ratio	95% CI	Cases	Hazard ratio	95% CI
Hydrophilic statin usec,d
Never	78	Ref.		34	Ref.		112	Ref.
Ever	12	1.54	0.79–3.03	8	2.22	0.99–4.98	20	1.80	1.07–3.01
Hydrophilic statin usec,d,e
Never	78	Ref.		34	Ref.		112	Ref.
Ever	12	1.52	0.70–3.30	8	2.28	0.93–5.63	20	1.81	1.00–3.25
Lipophilic statin usec,f
Never	78	Ref.		34	Ref.		112	Ref.
Ever	23	1.25	0.75–2.07	23	1.27	0.74–2.18	46	1.26	0.87–1.82
Lipophilic statin usec,e,f
Never	78	Ref.		34	Ref.		112	Ref.
Ever	23	1.32	0.73–2.39	23	1.34	0.70–2.58	46	1.33	0.86–2.07
Ever statin use
Never	78	Ref.		34	Ref.		112	Ref.
Ever	53	1.41	0.94–2.10	38	1.21	0.75–1.93	91	1.32	0.97–1.79
Ever statin usee
Never	78	Ref.		34	Ref.		112	Ref.
Ever	53	1.43	0.86–2.36	38	1.31	0.74–2.35	91	1.38	0.94–2.02

HPFS health professionals follow up study, NHS nurses’ health study, NHSII nurses’ health study II

^aObtained via meta-analysis of NHS and NHSII cohorts using the fixed effect model

^bObtained via meta-analysis of NHS, NHSII, and HPFS cohorts using the fixed effect model

^cTotals for specific statin types may not sum to total case counts due to exclusion of all participants who did not specify statin brand

^dHydrophilic statins were considered Crestor® (rosuvastatin) and Pravachol® (pravastatin)

^eAdjusted for hypertension (yes vs. no), hyperlipidemia (yes vs. no), diabetes (yes vs. no), body mass index (> 25 vs. 25–29.9 vs. > 30 vs. unknown kg/m²), and smoking status (never vs. past vs. current vs. unknown)

^fLipophilic statins were considered Mevacor® (lovastatin), Zocor® (simvastatin), and Lipitor® (atorvastatin)